Shareholders meeting

Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 01 October 2026 National Stock Exchange of India Limited BSE Limited Scrip Symbol: SUNPHARMA Scrip Code: 524715 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations”) - Notice of Postal Ballot/E-voting This is to inform that the Company is conducting a Postal Ballot/E-voting to seek shareholders’ approval for the below items: Item No. Particulars of the Approval Sought as Special Resolutions Approval of the Sun Pharma Employees Stock Option Plan 2026 (“ESOP 2026”) and Provision of Funds to the Trust 2. Approval of Secondary Acquisition of Equity Shares by the Trust 3. Approval for Extension of ESOP 2026 to Eligible Employees of Subsidiary Companies 4. Approval for Enhancement of Limits under Section 186 of the Companies Act, 2013 Approval for Enhancement of borrowing limit under Section 180(1)(c) of the Companies Act, 2013 6. Approval for Creation of Security under Section 180(1)(a) of the Companies Act, 2013 Approval for Creation of Encumbrance over Shares Pursuant to Regulation 24(5) of the SEBI Listing Regulations The Notice of Postal Ballot is being sent electronically to the Members whose email addresses are registered with the Company/Depositories and whose names appear in the Register of Members/List of Beneficial Owners as on the cut-off date. A copy of the Notice of Postal Ballot/E-voting (“Notice”) is enclosed herewith. The Notice is available on the Company’s website at www.sunpharma.com and the same can also be accessed by scanning the QR Code. The key dates relating to the Postal Ballot/e-voting process are set out below: Particulars Timeline Cut-off date for shareholders who are eligible for Friday, 25 September 2026 e-voting E-voting Begins Friday, 02 October 2026 at 09:00 A.M. IST E-voting Ends Saturday, 31 October 2026 at 05.00 P.M. IST Announcement of Voting Results On or before Tuesday, 03 November 2026 For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA Reaching People. Touching Lives SUN PHARMACEUTICAL INDUSTRIES LIMITED Registered Office: SPARC, Tandalja, Vadodara - 390012, Gujarat, India. Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai - 400063, Maharashtra, India. Tel: 022-43244324 CIN: L24230GJ1993PLC019050 | Website: www.sunpharma.com | Email: secretarial@sunpharma.com NOTICE OF POSTAL BALLOT / E-VOTING Cut-off Date Voting Opens Voting Closes Results 02 October 2026 31 October 2026 On or before 03 25 September 2026 09:00 A.M. IST 05:00 P.M. IST November 2026 Cut-off Date: Members whose names appear on the Register of Members / List of Beneficial Owners as on the Cut-off Date shall be entitled to vote. Index Sl. No. Section Page No. 1. Executive Summary 2-3 2. Notice of Postal Ballot / E-voting and Resolutions 4-9 3. Explanatory Statement 10-23 • Part A – Sun Pharma Employees Stock Option Plan (ESOP 2026) and Connected Matters • Part B - Funding and Acquisition and Connected Matters 4. Statutory Notes 24 5. E-voting Instructions 25 The Notice of the Postal Ballot / E-voting and Explanatory Statement is prepared pursuant to the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. Sun Pharmaceutical Industries Limited | Postal Ballot Notice – October 2026 Page 1 of 25 This Postal Ballot is divided into two parts, each covering a specific objective and proposals. Part A – Sun Pharma Employees Stock Option Plan (ESOP 2026) and Connected Matters Part A (Item No. 1 to 3) relate to the proposed Employee Stock Option Plan 2026 (“ESOP 2026”), which is intended to strengthen the Company’s long-term incentive framework by providing eligible employees with performance-linked, share-based rewards. The proposals cover adoption of ESOP 2026, acquisition of shares through a Trust for implementation of the Plan and extension of the Plan to eligible employees of subsidiary company(ies). The Board believes that these proposals will help attract, motivate and retain talent while aligning employee interests with long-term shareholder value creation. The Plan will be implemented using existing shares acquired from the secondary market and will not involve a fresh issue of shares by the Company thereby not involving any dilution. Part B - Funding and Acquisition and Connected Matters Part B (Item No. 4 to 7) relate to certain enabling approvals required in connection with the proposed acquisition of Organon & Co. and the associated financing arrangements. These proposals include enhancement of limits for investments, loans, guarantees, securities and borrowings, creation of security in favour of lenders and approval under Regulation 24(5) of the SEBI Listing Regulations. These approvals are intended to facilitate implementation framework necessary to support the proposed acquisition and related funding requirements. Executive Summary of the Proposals This Executive Summary provides a brief overview of the proposals and should be read together with the respective resolutions, Explanatory Statement and notes forming part of this Notice. Item Resolution Subject Matter Rationale No. Type PART A 1. Approval of the Sun Pharma Employees Stock Option Plan 2026 To strengthen the Company’s long-term performance linked Special and Provision of Funds to the Trust incentive framework by transitioning to Share-based awards against Cash settled awards to further align employee interests with long-term shareholder value creation. 2. Approval of Secondary Acquisition of Equity Shares by the Trust To obtain the separate shareholder approval required under the Special SBEB Regulations for acquisition of shares from the secondary market through the Trust for implementation of ESOP 2026. 3. Approval for Extension of ESOP 2026 to Eligible Employees of To provide a common and consistent performance, incentive Special Subsidiary Companies and retention framework extended to eligible employees of the subsidiary company(ies). PART B 4. Approval for Enhancement of limits under Section 186 of the To provide adequate limits for investments, loans, guarantees Special Companies Act, 2013 and securities in connection with the proposed acquisition, Sun Pharmaceutical Industries Limited | Postal Ballot Notice – October 2026 Page 2 of 25 related financing arrangements and future business requirements. 5. Approval for Enhancement of borrowing limit under Section To facilitate acquisition financing, payment of acquisition Special 180(1)(c) of the Companies Act, 2013 consideration, refinancing of existing indebtedness, other corporate funding requirements and future business requirements. 6. Approval for Creation of security under Section 180(1)(a) of the To enable the Company to provide security in connection with Special Companies Act, 2013 borrowings and financing arrangements supporting the proposed acquisition and related funding structure. 7. Approval for Creation of Encumbrance over Shares Pursuant to To seek shareholder approval under Regulation 24(5) of the Special Regulation 24(5) of the SEBI Listing Regulations SEBI Listing Regulations in connection with the proposed creation of security over shares of Organon and/or certain subsidiaries through which the acquired business may be held, in anticipation of the completion of the Proposed Acquisition. E-Voting [Friday, 02 October 2026 at 09:00 A.M. (IST) until Saturday, 31 October 2026 at 05:00 P.M. (IST)] EVENT Scan to Vote (CDSL) Scan to Vote (NSDL) Voting Instructions 260919 Sun Pharmaceutic [Showing first 8,000 characters — download PDF for full document]